About OcellO
OcellO is a Healthcare company based in Leiden (Netherlands) founded in 2011, and was acquired by Crown Bioscience in May 2021. 3D screening services for drug discovery are offered. OcellO offers products and services including PDX Models, Genomics Services, Proteomics Services, CRISPR/Cas9 Services, and Bioanalytical Services. Its focus areas include Biopharma Outsourcing, CRO, Preclinical Studies and Diversified.
Company details
OcellO is a CRO that provides 3D screening services for drug discovery. It has a proprietary high throughput system for 3D imaging and phenotypic profiling that enables better quantification of complex biological phenomena combined with clinically relevant endpoints. Based on this platform, the company offers several drug screening and discovery services, including development of target-specific and immuno-oncology assays for screening drugs, phenotypic screening in disease models of interest and compound profiling, as well as a specialized drug candidate testing platform for polycystic kidney disease. In addition, OcellO offers in vitro 3D cell culture assays of patient-derived xenograft (PDX) mouse models for lead optimization, in partnership with Charles River Laboratories.
- Headquarters Leiden, Netherlands
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website ocello.nl
- Social LinkedIn Facebook
- Acquired by Crown Bioscience (May 2021)
- Latest Funding Round$325.75K (USD), Grant
Jan 2021
- InvestorsCrown Bioscience
& 1 more
- Acquired byCrown Bioscience
(May 2021)
Products & Services of OcellO
OcellO offers a comprehensive portfolio of products and services, including PDX Models, Genomics Services, Proteomics Services, CRISPR/Cas9 Services, and Bioanalytical Services.
Preclinical models for tumor drug testing and research
DNA sequencing and analysis for biomarker discovery
Mass spectrometry-based analysis for protein studies
Gene editing tools for cell line development
Testing for biomarkers and drug responses
Funding Insights of OcellO
- Total Rounds 3
- Last Round Grant — $325,747
- First Round $159,679
(Sep 2017)
- Investors Count 1
All 3 funding rounds of OcellO with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2021 | $325,747 | Grant | – | – | |
| Feb 2018 | $289,153 | Grant | – | – | |
| Sep 2017 | $159,679 | Grant | – | – |
2 investors in total: 2 institutional.
Investors in OcellO
OcellO has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Crown Bioscience and European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
Cancer and CVMD drugs are developed using PDX models. | 2006 | crownbio.com | Santa Clara, United States |
Investor details for OcellO
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of OcellO
4 dated milestones of OcellO across 10 years, from founding to its latest funding, stage changes and deals.
- Founded OcellO is founded.
- Funding First funding round of $160K.
- Funding Latest funding round, Grant, of $326K.
- Exit Acquired by Crown Bioscience.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Ocello
Complete news archive for OcellO
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about OcellO
OcellO was founded in 2011 and raised its 1st funding round 6 years after it was founded.
OcellO is headquartered in Leiden, Netherlands. It is registered at Leiden, South Holland, Netherlands.
OcellO is a CRO that provides 3D screening services for drug discovery. It has a proprietary high throughput system for 3D imaging and phenotypic profiling that enables better quantification of complex biological phenomena combined with clinically relevant endpoints. Based on this platform, the company offers several drug screening and discovery services, including development of target-specific and immuno-oncology assays for screening drugs, phenotypic screening in disease models of interest and compound profiling, as well as a specialized drug candidate testing platform for polycystic kidney disease. In addition, OcellO offers in vitro 3D cell culture assays of patient-derived xenograft (PDX) mouse models for lead optimization, in partnership with Charles River Laboratories.
OcellO offers PDX Models, Genomics Services, Proteomics Services, CRISPR/Cas9 Services, and Bioanalytical Services.
OcellO has 2 investors. Key investors include Crown Bioscience, and European Union.
Yes. OcellO was acquired by Crown Bioscience in May 2021.